Home Cart Sign in  
Chemical Structure| 1268454-23-4 Chemical Structure| 1268454-23-4

Structure of Serabelisib
CAS No.: 1268454-23-4

Chemical Structure| 1268454-23-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MLN1117 is a selective p110α inhibitor with IC50 of 15 nM.

Synonyms: MLN1117; INK1117; TAK-117

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Serabelisib

CAS No. :1268454-23-4
Formula : C19H17N5O3
M.W : 363.37
SMILES Code : O=C(C1=CN=C2C=CC(C3=CC=C(OC(N)=N4)C4=C3)=CN21)N5CCOCC5
Synonyms :
MLN1117; INK1117; TAK-117
MDL No. :MFCD15146372
InChI Key :BLGWHBSBBJNKJO-UHFFFAOYSA-N
Pubchem ID :70798655

Safety of Serabelisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Serabelisib

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110α

    PI3Kα, IC50:21 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
TIB-48 9.75μM Evaluate the inhibitory activity of MLN1117 on TIB-48 cells PMC5725023
Jurkat 36.45μM Evaluate the inhibitory activity of MLN1117 on Jurkat cells PMC5725023
CRL-2396 21.37μM Evaluate the inhibitory activity of MLN1117 on CRL-2396 cells PMC5725023
B cells 1 μM 3 days Evaluate the effect of MLN1117 on B cell proliferation, results showed 1 μM MLN1117 had no significant effect on B cell proliferation PMC3581375
U87MG cells 125 nM to 2 μM 48 hours Evaluate the effect of MLN1117 on U87MG cell growth, results showed MLN1117 had no significant effect on cell growth at concentrations from 125 nM to 2 μM PMC3581375
SK-OV-3 cells 125 nM to 2 μM 48 hours Evaluate the effect of MLN1117 on SK-OV-3 cell growth, results showed MLN1117 significantly inhibited cell growth at concentrations from 125 nM to 2 μM PMC3581375

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Balb/cJ mice Oral gavage 60 mg/kg Daily administration for 13 days Evaluate the effect of MLN1117 on immune responses in mice, results showed 60 mg/kg MLN1117 did not affect NP-specific IgM or IgG1 responses PMC3581375
Mice C57BL/6 mice Oral 60 mg/kg Once daily for 7 days To evaluate the effect of MLN1117 on NK cell maturation and function. Results showed that MLN1117 had negligible effects on NK subset maturation or terminal subset commitment. PMC4051752
BALB/c mice PTCL xenograft model Oral 30 mg/kg Once daily for 3 weeks Evaluate the anti-tumor activity of alisertib combined with MLN1117 in a PTCL xenograft model, showing significant tumor growth inhibition PMC5725023

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01449370 Metastatic Solid Tumors PHASE1 COMPLETED 2025-01-16 Boston, Massachusetts, United ... More >>States|Detroit, Michigan, United States|Dallas, Texas, United States|Barcelona, Spain|Sutton, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.75mL

0.55mL

0.28mL

13.76mL

2.75mL

1.38mL

27.52mL

5.50mL

2.75mL

References

 

Historical Records

Categories